Wednesday, May 27, 2026

Talcum Powder and Depo-Provera Drive Daily Mass Tort Filings

We tracked 89 new filings yesterday, with daily volume heavily driven by established pharmaceutical and consumer product liability dockets. The MDL 2738 (Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation) led the field with 23 filings, primarily brought by Wagstaff Law Firm alongside Frazer PLC and DV Injury Law. Close behind, the MDL 3140 (Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation) saw 21 filings, spearheaded by Levin Papantonio and Seeger Weiss. The MDL 3060 (Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation) generated 10 filings, largely driven by Aylstock Witkin Kreis Overholtz PLLC. The MDL 3094 (Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation) drew 6 filings from firms including Morgan & Morgan PA and Morris Bart. Rounding out the top tier, the MDL 2846 (**Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation**) saw 5 filings handled exclusively by Lanier Law Firm.

Australia Launches $1.4 Billion Lawsuit Against 3M Over PFAS Contamination

On May 28, 2026, the Australian federal government launched a historic $1.4 billion lawsuit against manufacturing giant 3M over widespread environmental contamination caused by per- and polyfluoroalkyl substances (PFAS). The legal action, filed in the Federal Court of Australia, seeks to recover extensive costs related to the investigation and remediation of "forever chemicals" at 28 Department of Defence bases across the country. Government officials allege that 3M withheld internal laboratory testing demonstrating the severe environmental impact of its aqueous film-forming foam (AFFF) and misrepresented the products as safe and biodegradable. 3M has stated it will defend itself against the claims, asserting it ceased selling the specific firefighting foams in Australia approximately two decades ago. This aggressive regulatory action signals a significant expansion of international liability for PFAS manufacturers following massive settlements previously reached in the United States.

New Meta-Analysis Links Semaglutide to Rare Optic Neuropathy Risk

On May 21, 2026, a comprehensive systematic review and meta-analysis published in PLOS Medicine identified a statistically significant association between semaglutide use and an increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in patients with Type 2 diabetes. The research aggregates large-scale observational data, finding a hazard ratio of 2.17 — an approximately two-fold relative risk increase — for developing the irreversible vision-loss condition compared to those on other glucose-lowering medications. The absolute risk remains very rare: roughly 0.014%, or about one additional NAION case per 7,000 treated patients annually. The findings note that this risk signal is most consistent in the diabetic population rather than those using the drug exclusively for weight management. For plaintiffs' attorneys monitoring the broader landscape of GLP-1 litigation, this peer-reviewed evidence provides a critical scientific anchor for emerging failure-to-warn claims surrounding severe ocular injuries.